MacuHealth Revenue and Competitors

Macular Degeneration is a degenerative eye disease and the leading cause of blindness in people over the age of 50 in North America. Low Macular Pigment (MP) is a major risk factor for Macular Degeneration. Macuhealth with LMZ3 is a patented nutritional supplement that contains the three pigments found in the macula. Regular intake of Macuhealth with LMZ3 has been shown to restore macular pigment to normal levels (up to 40% increase in MP over a 6 month period). MacuHealth was founded in 2006 by Frederic Jouhet with the following goals in mind: 1. Provide a unique, effective dietary solution to AMD by combing the correct levels of carotenoids found in macular pigment. (Lutein, Zeaxanthin and Meso-Zeaxanthin). 2. Prioritize scientific research and enlist world class scientists to prove the formula's efficacy and safety through peer-reviewed studies. With multiple reviewed publications that demonstrate the formula's efficacy and safety, plus a passion for protecting eyesight, MacuHealth is at the forefront of preventative treatments for macular disease. The company holds both worldwide exclusivity and a patent on the science-based 10-10-2 formulation. With help from its distribution groups around the world, MacuHealth (MacuShield in Europe) has become the supplement of choice in the fight against AMD and enhancement of visual function worldwide.